In patients with type 2 diabetes (T2D), dual therapy with metformin and GLP-1 receptor agonists (RAs) was associated with a 39% lower risk for adiposity-related cancers and a 67% lower risk for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback